Introduction
Rheumatoid arthritis (RA) is an inflammatory disease that affects 1% of the general population [1] . It is characterized by pain in multiple joints and destruction of the bone and cartilage in joints. Ultimately, it can result in disability and loss of function. In recent years, there has been marked progress in the development of disease-modifying antirheumatic drugs (DMARDs) for RA. In particular, a number of biological DMARDs that target specific molecules in the immune system have been shown to exert rapid and powerful effects in patients who cannot tolerate, or whose disease is refractory to, conventional synthetic DMARDs such as methotrexate (MTX) [2] . However, there are also subsets of patients who cannot tolerate or whose disease is refractory to biological therapies. In addition, biological DMARDs associate with a higher risk of infections, especially the reactivation of latent tuberculosis; these safety concerns can limit the usefulness of these drugs [3, 4] . Therefore, there is still a high demand for effective but safe and tolerable treatments for RA.
The human reverse transcriptase subunit of telomerase (hTERT) is an attractive target in cancer because it is overexpressed by the majority of human tumors and is absent in most benign adult tissues. GV1001 (Tertomotide, GV1001TM) is a vaccine that consists of a16-mer peptide that corresponds to amino acids 611-626 of hTERT (EARPALLTSRLRFIPK). This is a highly promiscuous peptide that binds to a wide variety of human leukocyte antigen (HLA)-DR, -DP and -DQ molecules [5, 6] . This promiscuity explains why phase I/II clinical trials show that this vaccine elicits T-helper responses in 50-80% of patients with pancreatic adenocarcinoma [7] , non-small cell lung cancer [8, 9] , or malignant melanoma [10] . GV1001 also harbors putative HLA-Class I epitopes; a study examining the T-cell responses of patients with lung cancer, colon cancer or melanoma who were vaccinated with GV1001 suggested that this vaccine may elicit both CD4+ and CD8+ T-cell responses [11] .
GV1001 not only acts as a cancer vaccine, it also exhibits anti-inflammatory activity: when mice were subcutaneously transfused with this peptide 30 min before and 12 h after kidney transplantation, they were protected from the development of renal ischemic-reperfusion injury [12] . This suggests that this peptide could be used as a candidate for immune modulation or anti-inflammation therapy. This possibility is supported by a phase III clinical trial on patients with pancreatic cancer, which showed that repeated treatment with GV1001 was safe and highly tolerable for the patients [13] . This suggests that this peptide may also be suitable for the long-term treatment of RA. To test this hypothesis, we assessed the effect of GV1001 treatment on joint inflammation in mice with collagen-induced arthritis (CIA), which is a model of human RA. We also investigated the effect of the peptide on in vitro models of RA, namely, RA effector cells, macrophages, and fibroblast-like synoviocytes (FLS).
Methods

Induction of collagen-induced arthritis
CIA was induced in 7-9-week-old DBA/1 mice (Harlan, Netherlands) in specific pathogen-free conditions. Briefly, after 7 days of acclimation, DBA/1 mice were injected intradermally at the base of the tail with 100 μg bovine type II collagen (CII; Chondrex, Inc. USA) emulsified in Freund's complete adjuvant (Day 0). A booster injection of 100 μg CII in Freund's incomplete adjuvant was given intradermally on Day 21 [14] . All experiments were approved by the Institutional Animal Care and Use Committee of Seoul National University Hospital Biomedical Research Institute (IACUC No. 12-0198).
Treatment schedules with CIA mice
Five experiments with mice that involved different GV1001 treatment schedules and doses were performed (Fig. S1 ). The first experiment consisted of five groups of CIA mice (n = 8 per group): two groups received preventive GV1001 treatment (two doses) and two groups received therapeutic GV1001 treatment (two doses). The fifth group was a control arthritis group that did not undergo GV1001 treatment. The two preventive GV1001 groups received 5 or 50 pmol/kg GV1001 in 0.1 mL 5% dextrose solution intradermally starting 1 day after the first priming injection with CII (i.e., Day 1). This was followed by the same GV1001 treatment on Days 3 and 5. This week 1 treatment schedule was repeated in the third and fifth week after the priming CII injection. Thus, the preventive GV1001 treatments were given on Days 1, 3, 5, 15, 17, 19, 29, 31 , and 33. The two therapeutic GV1001 groups received 5 or 50 pmol/kg GV1001 intradermally starting 1 day after the CII booster injection (i.e., Day 22). This was followed by the same GV1001 treatment 2 and 4 days later. This week 4 treatment schedule was repeated in week 6. Thus, the therapeutic GV1001 treatments were given on Days 22, 24, 26, 36, 38, and 40. All animals scored for CIA incidence and severity every 2 days starting the day after the booster CII injection (i.e., Day 22). They were sacrificed on Day 42 (Fig. S1A) .
The second experiment consisted three groups of CIA mice (n = 8 per group). One group was injected with GV1001 vehicle alone and served as the arthritis control. The other two groups were given therapeutic GV1001 treatment by intradermal injections of 1 and 5 pmol/kg GV1001 starting the day after the CII booster injection (i.e., Day 22). The treatment doses were on Days 22, 24, 26, 36, 38, and 40. All animals scored for CIA incidence and severity every 2 days starting the day after the booster CII injection (i.e., Day 22). All mice were sacrificed on Day 42. Sera were collected on the day of sacrifice (Fig. S1B) .
The third experiment consisted of four groups of mice (n = 14 per group). Three underwent CIA induction while the remaining group remained naïve. The three CIA groups underwent therapeutic treatment with intradermal 1 pmol/kg GV1001, 1 pmol/kg control peptide, or 0.1 mL vehicle, respectively. The treatment started on the day after the CII booster injection (i.e., Day 22). The treatment doses were on Days 22, 24, 26, 36, 38, and 40. The control peptide (PEP164) was a scrambled peptide of GV1001 that consisted of the same amino acids but with a different sequence (PKRPSRFIEALTRPLR). All animals were weighed and scored for CIA incidence and severity every 2 days starting the day after the booster CII injection (i.e., Day 22). Half of the mice in each of the four groups were sacrificed on Day 49; the remaining mice were sacrificed on Day 98. Just before sacrifice, sera were taken. Just after sacrifice, the splenocytes and joints were harvested for further analysis (Fig. S1C) .
The fourth experiment consisted of three groups of CIA mice (n = 6 in GV1001 group, n = 5 in MTX group and n = 8 in vehicle group). The three groups underwent therapeutic treatment with intradermal injections of 1 pmol/kg GV1001, 3 mg/kg MTX, or 0.1 mL vehicle, respectively. The treatment started on Day 30, after CIA mice developed arthritis. The treatment doses were given on Days 30, 32, 34, 45, 60, 75 and 90 to the GV1001 group and vehicle group and on Days 30, 32, 34, 36, 38 and 40 to the MTX group (Fig. S1D) .
The fifth experiment consisted of three groups of CIA mice (n = 4 in GV1001 group, n = 4 in MTX group and n = 5 in vehicle group). The three groups underwent therapeutic treatment with intradermal injections of 1 pmol/kg GV1001, 3 mg/kg MTX, or 0.1 mL vehicle, respectively. The treatment started on Day 35, after CIA mice developed arthritis. The treatment doses were given on Days 35, 37, 39, 50, 65, 80 and 95 to the GV1001 group and on Days 35, 37 and 39 to the MTX group (Fig. S1E ).
Clinical joint scoring
The severity of arthritis was assessed by blinded examination every 2 days starting the day after the booster CII injection (i.e., Day 22). The assessments were continued until the day of sacrifice. Clinical arthritis scores were determined by using a scale of 0-4, where 0 = normal, 1 = apparent redness and swelling limited to individual digits, 2 = moderate redness and swelling of the ankle or wrist, 3 = severe redness and swelling of the entire paw including digits, and 4 = maximally inflamed limb with involvement of multiple joints (Figs. 1-2). Each limb was graded. Thus, the maximum score of each mouse on each scoring day was 16.
Serum cytokine levels and histology
Murine serum IL-1β, IL-6, IL-10 and TNF-α levels were measured by using Bio-Plex Pro™ cytokine assays (BioRad, USA), according to the manufacturer's instructions. For histological examination, both posterior limbs were fixed in 10% formalin, decalcified in EDTA, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. A 0-4 subjective grading system (0 = normal; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe) was used to evaluate synovial proliferation, bone erosion, cartilage damage, and leukocyte inflammation. The total histological score of a joint is the sum of the scores of the four variables (0-16 scale).
Measurement of CII-specific T-cell responses
The splenocytes harvested from the Experiment 3 mice on Days 49 and 98 were used to analyze the effect of GV1001 treatment on the CII-specific T-cell cytokine responses of the mice in vitro. Thus, the single-cell suspensions were prepared and splenocytes (5 × 10 5 cells/ well in 96-well flat-bottom plates) were re-stimulated in triplicate with 50 μg/mL bovine CII plus 2.5 μg/mL GV1001 or control peptide. After 72 h, the culture supernatants were collected and assessed for the presence of IFN-γ, and IL-6 by using the enzyme-linked immunosorbent assay (ELISA, OPTEIA Mouse cytokine set, BD Pharmingen).
Effect of GV1001 on human and murine macrophages
The human monocyte cell line THP-1 and the mouse monocyte cell line RAW 264.7 were cultured in 24-well plates (1.0 × 10 5 cells/well) with 100 ng/mL phorbol myristate acetate (PMA) for 20 h. Following differentiation into macrophages, the cells were washed twice with complete Roswell Park Memorial Institute (RPMI) 1640 growth medium and then treated with 10 ng/mL lipopolysaccharide (LPS) with or without 0.001, 0.01, 0.1, 1, or 10 μM GV1001 in 1 mL of serum-free RPMI 1640 for 4 h. Supernatant samples were then collected and analyzed for TNF-α and IL-6 using ELISAs.
Effect of GV1001 on human fibroblast-like synovial cells
Synovial fibroblast cells were prepared from synovial samples obtained from three RA patients (LSC, YSL, BYK) who had undergone joint replacement surgery as described previously [15] . FLS were used in experiments after four to six passages. 
plates, and incubated until the confluence reached 90%. Each well was then washed with warm PBS twice and pre-treated with 1 mL of 0.001, 0.1 and 10 μM GV1001 in serum-free medium for 2 h. TNFα was then added to a final concentration of 10 ng/mL and the cells were incubated for an additional 12 h, after which 1 mL of cell culture supernatant was collected and centrifuged at 1300 rpm for 10 min. Thereafter, 850 μL supernatant was placed into a new tube. The supernatant was subjected to ELISA to measure IL-6 production. These experiments were approved by the Seoul National University Hospital Institutional Review Board (IRB No. 1410-113-619).
Statistical analysis
Statistical analyses were performed by using IBM SPSS statistics version 22 (Chicago IL, USA) and the graphics were generated by using GraphPad Prism version 5 (GraphPad, La Jolla CA, USA). The changes (slopes) in longitudinal clinical joint scores for each treatment group were compared using summary measure analysis. Group means were compared by using the Mann-Whitney U test or ANOVA. pValues b 0.05 were considered statistically significant.
Results
Changes in clinical joint scores after preventive and therapeutic GV1001 treatment (Experiment 1)
The CIA mice that were treated preventively with 5 and 50 pmol/kg GV1001 did not exhibit improved clinical joint scores compared to the arthritis control mice. This was also the case for the CIA mice that were treated therapeutically with 50 pmol/kg GV1001. However, the CIA mice that were treated therapeutically with 5 pmol/kg GV1001 tended to have a lower mean clinical joint score on Day 42 than the arthritis control mice (5.33 ± 2.73 vs. 7.17 ± 2.79), although the difference did not achieve statistical significance (p = 0.251, Fig. S2 ). Given this result, the second CIA experiment was performed to identify the optimal dose; thus, mice were treated therapeutically with doses of around 5 pmol/kg.
3.2.
Changes in clinical joint scores and murine serum IL-6 levels after therapeutic treatment with 1 and 5 pmol/kg GV1001 (Experiment 2) Therapeutic treatment with 1 and 5 pmol/kg GV1001 tended to improve clinical joint scores compared with the arthritis control, although these differences did not achieve statistical significance (p = 0.068 and p = 0.830, respectively; Fig. 1A ). However, both treatments significantly reduced the serum IL-6 levels on the day of sacrifice (Day 42) (both p b 0.01; Fig. 1B ). The two GV1001 doses did not differ significantly from each other in terms of either joint scores or serum IL-6 levels.
Effect of GV1001 and control peptide treatment for 98 days on clinical joint scores, serum cytokine levels, and histological joint scores, and CII-specific splenocyte responses (Experiment 3)
The GV1001-treated group had significantly lower clinical joint scores than the vehicle-treated group on Days 57-64 (p b 0.01 Fig. 2A ). In addition, the area under the curve (AUC) for the clinical joint score over the 98 day observation period was significantly smaller in the GV1001-treated group than in the vehicle-treated group (p b 0.05; Fig.  2B ). The GV1001-treated group also weighed significantly more than the vehicle-treated group on Days 57-64 (p b 0.05) and 78-87 (p b 0.01; Fig. 2C ). The AUC for weight over the 98 day observation period was also significantly larger in the GV1001-treated group than in the vehicle-treated group (p b 0.05; Fig. 2D ). The control peptide-treated group did not differ significantly from the arthritis controls in terms of clinical joint scores, AUC for the clinical joint score, weight, or AUC for weight.
The three groups did not differ significantly in terms of serum IL-1β, IL-6, IL-10, and TNF-α levels on Day 49 (Fig. 3A) . However, on Day 98, the GV1001-treated mice had significantly lower IL-6 levels than the vehicle-treated group (p b 0.01; Fig. 3B ). Representative images of H&E-stained sections through the tibio-tarsal joints of a GV1001-treated mouse and a vehicle-treated mouse are shown in Fig. 4A . The GV1001-treated mice also had significantly lower total histological joint scores than the vehicle-treated mice on Day 98 (p b 0.05; Fig. 4B ). In terms of the four variables that constitute the total histological joint score, GV1001 treatment did not influence the Day 98 synovial proliferation scores relative to vehicle treatment (p = 0.06). However, GV1001 treatment did significantly reduce the Day 98 bone erosion, cartilage damage, and leukocyte infiltration scores relative to vehicle treatment (all p b 0.05). Treatment with the control peptide did not significantly influence the total histological score or the scores of the four variables.
The splenocytes that were harvested from the Experiment 3 mice on Days 49 and 98 were cultured with or without CII and their secretion of IFN-γ and IL-6 measured. In terms of Day 49 splenocytes, GV1001 treatment associated with significantly lower basal (p b 0.05) and CII-stimulated (p b 0.001) splenocyte secretion of IFN-γ compared to vehicle treatment (Fig. 5A ). This pattern was also observed for the Day 49 splenocyte secretion of IL-6 (p b 0.05 and b0.001, respectively) ( Fig. 5D) . lower clinical joint scores than the vehicle-treated group on Days 45-49 (p b 0.05, Fig. 6B ).
Effect of co-culture with GV1001 on inflammatory cytokine secretion by human and murine macrophages
Human (THP-1) and murine (RAW 264.7) monocyte cell lines were treated with PMA to induce differentiation into macrophages and then cultured with LPS in the presence and absence of several GV1001 concentrations. All GV1001 concentrations decreased the TNFα and IL-6 secretion of the LPS-stimulated THP-1 (all p b 0.05; Fig. 7A and B) and RAW 264.7 macrophages (all p b 0.01; Fig. 7C and D) .
3.6. Effect of co-culture with GV1001 on inflammatory cytokine secretion by TNFα-stimulated FLS When three FLS were stimulated with TNFα in the presence or absence of several concentrations of GV1001, GV1001 did not affect their secretion of IL-6, as shown by the results of ELISA (Fig. 7E ).
Discussion
In the CIA model, therapeutic GV1001 treatment that consisted of three weekly intradermal injections given during the first and third weeks after the CII booster injection significantly reduced clinical joint scores, histology scores, and serum IL-6 levels at 98 days after the priming CII injection. The most effective GV1001 dose was 1 pmol/kg. Therapeutic GV1001 treatment also decreased the basal and CII-stimulated IFN-γ and IL-6 secretion of splenic T-cells harvested 49 days after the priming injection. This effect on basal and CII-stimulated splenocyte secretion of IL-6 was particularly marked on Day 98. GV1001 did not have a direct anti-inflammatory effect on FLS from RA patients but did decrease the inflammatory cytokine secretion of LPS-stimulated THP-1 and RAW 264.7 macrophages. These observations together suggest that GV1001 may ameliorate joint inflammation by modifying T-cell immune reactions to the triggering autoantigen and by reducing macrophage cytokine production. In addition, the results of preventive treatment with GV1001, which was not beneficial in the case of mouse arthritis, suggests that modulation of the T-cell immune reaction is probably the dominant mechanism mediating the preventative effect of GV1001 on arthritis and that treatment with GV1001 might not work when it is administered in the absence of active T-cell immune responses.
The development of arthritis in the CIA model is dependent on T-cell immune responses against collagen. Similar to CIA, the development of RA depends on pathogenic T-cell responses against various autoantigens such as citrullinated proteins. If GV1001 can modulate Tcell immune responses in RA patients, it has the potential to serve as an immunotherapy (i.e., a therapeutic RA vaccine). Several such epitope-specific immunotherapies for RA have been developed to date. Of these, the tolerizing oral therapy with dnaJP1 is a leading example. A phase II clinical trial showed that this treatment tended to associate with clinical improvement [16] while a study with early RA patients revealed that this epitope-specific mucosal therapy caused their antigenspecific T-cells to readjust from a pro-inflammatory to a regulatory phenotype [17] . This effect was associated with modest efficacy in specific subsets of RA patients and was suggested to act synergistically with hydroxychloroquine and anti-cytokine therapies such as etanercept [18, 19] .
In the Experiment 3, not only GV1001 but also the control peptide significantly reduced basal IFN-γ and IL-6 secretion and CII-stimulated IL-6 production by splenocytes from the CIA mice on Day 98. In addition, the control peptide also had a tendency to reduce joint inflammation in these mice. We presume that the inhibitory effects of GV1001 on T cell responses might be partly nonspecific, and that GV1001 and the control peptide might act nonspecifically to prevent CIA induction. However, GV1001 was significantly more effective than the control peptide in suppressing joint inflammation. At present, we are unable to explain the differences in the efficacy of the two peptides.
Experiment 4 and 5 showed that GV1001 treatment is more efficacious when administered as an early treatment. Also, GV1001 showed a treatment response comparable to that of MTX, which was the first line RA treatment in these two experiments.
The sequence of TERT differs in mice and humans. Thus, it remains possible that GV1001 may not have the same effects on the T-cell responses of humans with RA as it does in mice. This is the major limitation of this study. However, there is considerable homology between the 16-mer sequence of GV1001 and the corresponding sequence in human TERT: the seven carboxy-terminal amino acids of GV1001 are identical to the human TERT sequence and the other nine amino acids also show some similarities (Fig. S3 ). This suggests that GV1001 can be recognized by murine T-cells and can induce cross-reactive T-cell responses. It also suggests that the anti-arthritic effects of GV1001 could be more powerful in human patients with RA than in the murine model of RA. In vitro studies on the responses of human macrophages to murine TERT and murine macrophages to human TERT are needed to test the immune cross-reactivity to the GV1001 sequence. Moreover, a phase I clinical trial is needed to characterize the immune responses of humans to GV1001. Clinical trials that assess the usefulness of GV1001 as a therapy for RA are also warranted.
Patients with RA usually require long-term anti-rheumatic drug treatment but this approach is often limited by the toxicity of the drugs. GV1001 treatment was safe and well-tolerated in a large phase III clinical trial for pancreatic cancer [13] . It also induces immune responses in various HLA backgrounds, including HLA-DR4 [20] , which is a well-known genetic risk factor of RA. Therefore, GV1001 therapy that modulates the immune responses in RA might be an option for the treatment of refractory RA or for patients who are particularly prone to the toxicity of standard anti-rheumatic therapy. Firm evidence of the therapeutic effect of this peptide in RA will have to await the outcomes of human trials.
Conclusions
Therapeutic GV1001 treatment reduced clinical joint scores, serum IL-6 levels, and histological joint scores in CIA mice and the treatment response was better when GV1001 was administered as an early treatment. It also reduced the CII-stimulated in vitro secretion of IFN-γ and IL-6 by murine T-cells from these mice. In addition, GV1001 decreased the TNF-α and IL-6 secretion by LPS-stimulated murine and human macrophages. These observations together suggest that GV1001 may ameliorate joint inflammation by modifying T-cell reactions to autoantigens; it may also act by reducing the pro-inflammatory cytokine production of macrophages. Fig. 7 . GV1001 inhibits TNFα and IL-6 release by lipopolysaccharide (LPS)-stimulated human and murine monocyte cell lines but has no effect on the IL-6 production of TNF-α-stimulated fibroblast-like synoviocytes from rheumatoid arthritis patients. (A-D) Human THP-1 monocytes (A, B) and murine RAW 264.7 monocytes (C, D) were induced to differentiate into macrophages and then treated with LPS in the presence or absence of serially-diluted GV1001. TNF-α (A, C) and IL-6 (B, D) secretion was measured and expressed as the mean and standard error. *p b 0.05, **p b 0.01, compared to the LPS-only control, as determined by the Mann-Whitney U test. (E) Fibroblast-like synoviocytes from three patients with rheumatoid arthritis were stimulated with TNF-α and IL-6 production was assessed by ELISA in the presence or absence of serially-diluted GV1001. Means and standard errors are shown. The GV1001-associated responses were compared with the TNF-α-only control (as determined by the Mann-Whitney U test); no statistically significant differences were observed.
